As emphasized [11,12], counteraction occurred as a general shared effect, given the counteraction of the muscle weakness with abdominal aorta anastomosis, stroke, traumatic brain injury, spinal cord compression, neuroleptic catalepsy, amphetamine hypermobility, hyperkalemia, hypokalemia, hypermagnesemia, hyperlithemia, insulin hypoglycemia, local anesthetics, neurotoxin (parkinsogenic 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine (MPTP), multiple sclerosis-like cuprizone), and tumor-induced muscle cachexia [11,12]
However, unlike the consistent long-term effect induced by L-NAME retrobulbar application, there was only limited detrimental retinal effect at 40 min after intravitreous L-NAME application in cats lasting only for 180 min [179]
Tone evens out Sun damage, redness, and discoloration fade as healthier cells replace damaged ones
Regulatory status further limits clinical use, since BPC-157 is not approved for medical treatment and available data remains largely experimental